瑞银证券有限责任公司（以下简称"瑞银证券"或"保荐机构"）作为上海 昊海生物科技股份有限公司（以下简称"昊海生科"或"公司"）首次公开发行 股票并在科创板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》、 《上市公司募集资金监管规则》、《上海证券交易所科创板股票上市规则》以及《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关规定， 就昊海生科使用闲置募集资金进行现金管理的情况进行了审慎核查，核查意见如 下： 一、投资情况概述 瑞银证券有限责任公司 关于上海昊海生物科技股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 （三）资金来源 1、本次现金管理的资金来源为公司 2019 年首次公开发行股份暂时闲置募集 资金。 2、募集资金基本情况 根据中国证券监督管理委员会于2019年9月27日出具的《关于同意上海昊海生 物科技股份有限公司首次公开发行股票注册的批复》（证监许可[2019]1793号）， 公司获准向社会公开发行人民币普通股1,780万股，每股发行价格为人民币89.23 元，募集资金总额为人民币1,588,294,000.00元；扣除发行费用后实际募集资金净 额为人民 ...

调整部分募投项目实施进度的核查意见 瑞银证券有限责任公司 关于上海昊海生物科技股份有限公司 瑞银证券有限责任公司（以下简称"瑞银证券"或"保荐机构"）作为上海昊海 生物科技股份有限公司（以下简称"昊海生科"或"公司"）首次公开发行股票并在 科创板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》、《上市公 司募集资金监管规则》、《上海证券交易所科创板股票上市规则》、《上海证券交易 所科创板上市公司自律监管指引第 1 号——规范运作》等相关规定，对昊海生科 调整部分募投项目实施进度事项进行了认真、审慎的核查，核查意见如下： 为规范公司募集资金管理和使用，保护投资者权益，公司设立了相关募集资 金专项账户。募集资金到账后，已全部存放于经公司董事会批准开设的募集资金 专项账户内，公司已与保荐机构、存放募集资金的商业银行签署了募集资金三方 监管协议。 二、募集资金投资项目的基本情况 截至 2025 年 10 月 31 日，公司首次公开发行募集资金投资项目的具体投入 情况如下： 单位：人民币万元 | 序号 | 项目 | 募集资金承 | 累计投入募 | 募集资金 | | --- | --- | --- | --- | ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-045 上海昊海生物科技股份有限公司 关于调整部分募投项目实施进度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海昊海生物科技股份有限公司（以下简称"公司"），于 2025 年 11 月 7 日 召开第六届董事会第五次会议审议通过了《关于调整部分募投项目实施进度的议 案》，同意上海昊海生科国际医药研发及产业化项目（以下简称"208 工程项目"） 部分药品车间实施进度调整至 2027 年 6 月达到预定可使用状态。本次调整实施 进度主要涉及 208 工程项目中药品车间工程的实施期限延长，经测算，该部分涉 及的须延期转固定资产的资产金额约占 208 工程项目使用募集资金总额的 15% 左右，不会对公司的正常生产经营产生重大不利影响。保荐机构瑞银证券有限责 任公司对本事项出具了明确的核查意见。该事项无需提交公司股东会审议。现将 相关情况公告如下： 一、募集资金基本情况 注 1：补充流动资金已累计投入总额人民币 20,135.79 万元，比募集资金承诺投资 ...

投资金额：不超过人民币 30,000 万元（含本数） 证券代码：688366 证券简称：昊海生科 公告编号：2025-046 上海昊海生物科技股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 已履行及拟履行的审议程序：上海昊海生物科技股份有限公司（以下 简称"公司"或"昊海生科"）于 2025 年 11 月 7 日召开第六届董事会第五 次会议，审议通过了《关于使用暂时闲置募集资金进行现金管理的议案》， 保荐机构瑞银证券有限责任公司（以下简称"保荐机构"）出具了无异议的 核查意见。该事项在董事会审批权限范围内，无须提交股东会审议。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：安全性高、流动性好、有保本约定的投资产品（包括但不 限于协定存款、通知存款、定期存款、大额存单、收益凭证等） 特别风险提示：尽管公司选择低风险投资品种的现金管理产品，但金 融市场受宏观经济的影响较大，公司将根据经济形势以及金融市场的变化适 时适量地介入，但不排除该项投资受到市场波动的影响。 2、募集资金基本情况 一、投资 ...

南财智讯11月7日电，昊海生科公告，公司于2025年11月7日召开第六届董事会第五次会议，审议通过了 《关于使用暂时闲置募集资金进行现金管理的议案》，同意使用不超过人民币3.00亿元的暂时闲置募集 资金进行现金管理，投资安全性高、流动性好、有保本约定的投资产品（包括但不限于协定存款、通知 存款、定期存款、大额存单、收益凭证等）。该事项自董事会审议通过之日起12个月内有效，资金在额 度范围内可滚动使用。公司强调，本次现金管理不会影响募集资金投资项目进度和公司正常生产经营。 ...

Investment Rating - The investment rating for the company is "Buy" with a maintained rating [6][17]. Core Views - The company has experienced a decline in revenue and net profit in the first three quarters of 2025, with revenue at 1.899 billion yuan, down 8.47% year-on-year, and net profit at 305 million yuan, down 10.63% year-on-year [1][2]. - The decrease in profit is attributed to an increase in VAT from 3% to 13% for products produced by its subsidiary, leading to a decline in revenue [2]. - The company is focusing on multi-level development in the medical beauty sector and accelerating the localization of the ophthalmic industry through self-research and investment integration [2][4]. Financial Performance - In the first three quarters of 2025, the company's gross margin was 70.39%, and the net margin was 15.51%, both remaining relatively stable year-on-year [3]. - The sales expense ratio increased by 2.97 percentage points to 31.62%, while the management expense ratio rose by 1.36 percentage points to 17.04% [3]. - The company’s R&D expense ratio decreased by 1.22 percentage points to 7.85% [3]. Product Development and Market Strategy - The company is actively developing new products, with significant advancements in clinical trials for its enhanced water-light injection products and high-permeability scleral lenses [3]. - The marketing strategy is being adjusted to enhance market share, utilizing a diverse range of hyaluronic acid products with differentiated effects and pricing [4]. - The company aims to optimize its sales structure to compensate for the loss of gross profit due to declining sales prices in the ophthalmic sector [2][4]. Revenue and Profit Forecast - Revenue forecasts for 2025-2027 are adjusted to 2.763 billion yuan, 3.006 billion yuan, and 3.287 billion yuan, respectively, reflecting a downward revision due to insufficient domestic consumption and price competition [4]. - The projected net profit for the same period is 423 million yuan, 473 million yuan, and 526 million yuan, respectively [4].

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 6, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks [1]. Group 1: Buyback Details - China Feihe (06186) repurchased 6.806 million shares for a total of 29.4298 million yuan, representing 0.746% of its total share capital [2]. - Kexin Pharmaceutical-B (02171) repurchased 1.734 million shares for 26.3078 million yuan, accounting for 0.380% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 1.53 million shares for 20.9869 million yuan, which is 0.409% of its total share capital [2]. Group 2: Other Notable Buybacks - Gushengtang (02273) repurchased 493,500 shares for 13.7699 million yuan, representing 3.435% of its total share capital [2]. - China Petroleum & Chemical Corporation (00386) repurchased 2.398 million shares for 10.1066 million yuan, which is 0.100% of its total share capital [2]. - Lianyi Technology-W (09959) repurchased 2.38 million shares for 7.4745 million yuan, accounting for 4.298% of its total share capital [2]. Group 3: Additional Companies - Other companies that conducted buybacks include: - Ruisheng Technology (02018) with 165,000 shares repurchased for 6.5033 million yuan [2]. - MGM China (02282) with 400,000 shares repurchased for 6.3701 million yuan [2]. - Huajian Medical (01931) with 922,000 shares repurchased for 5.9985 million yuan [2]. Group 4: Smaller Buybacks - Companies with smaller buyback amounts include: - Yidian Cloud (02416) with 130,000 shares repurchased for 264,000 yuan [3]. - International Home Retail (01373) with 150,000 shares repurchased for 118,500 yuan [3]. - Mobi Development (00947) with 70,000 shares repurchased for 1.167 million yuan [3].

Core Viewpoint - Haohai Biological Technology has been actively repurchasing its shares, indicating a strategy to support its stock price amid declining performance metrics in the medical aesthetics sector [1][4]. Share Buyback Activity - The company spent HKD 805,700 to repurchase 29,600 shares on November 5, marking the third consecutive trading day of buybacks in November [1]. - In total, Haohai has conducted 23 share buybacks this year, with 11 in the first half and 12 in the second half [1]. - The share buybacks in the second half were divided into two phases: the first from September 15 to September 24, and the second from October 27 to November 5 [1]. Financial Performance - For Q3 2025, the company reported revenue of CNY 594 million, a year-on-year decline of 11.29%, and a net profit of CNY 93.58 million, down 11.39% [4]. - Year-to-date revenue for the first three quarters was CNY 1.899 billion, down 8.47%, with a net profit of CNY 305 million, a decrease of 10.63% [4]. - The decline in revenue is attributed to insufficient domestic consumer demand, intensified industry price competition, and tax rate adjustments [4]. Business Segment Performance - The medical aesthetics segment generated CNY 575 million, accounting for 44.35% of total revenue, with hyaluronic acid products contributing CNY 347 million, down 16.80% [5]. - The epidermal growth factor products saw revenue of CNY 92.38 million, reflecting a growth of 13.73% [5]. Market Position and Valuation - Haohai's current PE (TTM) ratio is 14.82, below the industry average of 20, indicating potential undervaluation [3]. - Despite the stock price decline, the company maintains a net asset value of HKD 26.93 per share, providing an arbitrage opportunity for investors [7]. - Since August 20, 2023, the proportion of shares held by Hong Kong Stock Connect investors has increased from 30.35% to 35.78% [7]. Strategic Focus on Botulinum Toxin - The company has invested USD 31 million in Eirion to develop various botulinum toxin products, aiming to capture a share of the growing market [9]. - The medical aesthetics injection market is dominated by hyaluronic acid and botulinum toxin, which together account for 65% of the market [10]. - The domestic penetration rate for botulinum toxin is significantly lower than in mature markets, suggesting substantial growth potential [12]. Future Outlook - Despite current performance challenges, the company's ongoing development in the botulinum toxin sector may provide a pathway for recovery [14]. - The collaboration with Eirion is expected to yield new products that could enhance market presence and profitability in the future [14].

Core Viewpoint - Haohai Biological Technology has been actively repurchasing its shares, indicating a strategy to support its stock price amid declining performance metrics in the medical aesthetics sector [1][4]. Share Buyback Activity - The company spent HKD 805,700 to repurchase 29,600 shares on November 5, marking the third consecutive trading day of buybacks in November [1]. - In total, Haohai has conducted 23 share buybacks this year, with 11 in the first half and 12 in the second half [1]. - The second phase of buybacks occurred from October 27 to November 5, following an initial phase from September 15 to September 24 [1]. Financial Performance - For Q3 2025, the company reported revenue of CNY 594 million, a year-on-year decline of 11.29%, and a net profit of CNY 93.58 million, down 11.39% [4]. - Year-to-date revenue for the first three quarters was CNY 1.899 billion, down 8.47%, with net profit decreasing by 10.63% to CNY 305 million [4]. - The decline in revenue is attributed to insufficient domestic consumer demand, intensified industry price competition, and tax rate adjustments [4]. Business Segment Analysis - The medical aesthetics segment generated CNY 575 million in revenue, accounting for 44.35% of total revenue, with hyaluronic acid products contributing CNY 347 million, down 16.80% [4][6]. - The epidermal growth factor products saw a revenue increase of 13.73% to CNY 92.38 million [4][6]. Market Position and Valuation - Haohai's current PE (TTM) ratio stands at 14.82, below the industry average of 20 [3]. - Despite the declining stock price, the company maintains a net asset value of HKD 26.93 per share, providing potential profit opportunities for investors [8]. Strategic Focus on Botulinum Toxin - The company has entered a partnership with Eirion to develop botulinum toxin products, aiming to capture a share of the growing market [10][15]. - The botulinum toxin market is dominated by foreign brands, but there is significant room for growth in China, where the penetration rate is currently low compared to mature markets like the U.S. [12][13]. Industry Trends - The medical aesthetics market is experiencing a shift, with hyaluronic acid and botulinum toxin being the leading materials, comprising 98% of the injection market [10]. - The domestic market for collagen is growing rapidly, with a projected compound annual growth rate of 41.45% from 2023 to 2027 [11].

Core Viewpoint - Haohai Biological Technology has been actively repurchasing its shares, indicating a strategy to support its stock price amid declining performance metrics in the medical aesthetics sector [1][4]. Share Buyback Activity - The company spent HKD 805,700 to repurchase 29,600 shares on November 5, marking the third consecutive trading day of buybacks in November [1]. - In total, Haohai has conducted 23 share repurchase operations this year, with 11 in the first half and 12 in the second half [1]. - The share buybacks are segmented into two phases: the first from September 15 to September 24, and the second from October 27 to November 5 [1]. Financial Performance - For Q3 2025, the company reported revenue of CNY 594 million, a year-on-year decline of 11.29%, and a net profit of CNY 93.58 million, down 11.39% [4]. - Year-to-date revenue for the first three quarters was CNY 1.899 billion, down 8.47%, with net profit decreasing by 10.63% to CNY 305 million [4]. - The decline in revenue is attributed to insufficient domestic consumer demand, intensified industry price competition, and tax rate adjustments [4]. Business Segment Analysis - The medical aesthetics segment generated CNY 575 million in revenue, accounting for 44.35% of total revenue, with hyaluronic acid products contributing CNY 347 million, down 16.80% [4][6]. - The epidermal growth factor products saw a revenue increase of 13.73% to CNY 92.38 million [4][6]. Market Position and Valuation - Haohai's current PE (TTM) ratio stands at 14.82, below the industry average of 20 [3]. - Despite the declining stock price, the company maintains a net asset value of HKD 26.93 per share, providing potential profit opportunities for investors [8]. Strategic Focus on Botulinum Toxin - The company has entered a partnership with Eirion to develop botulinum toxin products, aiming to capture a share of the growing market [10][15]. - The botulinum toxin market is seen as a promising area for growth, with significant potential for market penetration in China compared to more mature markets like the U.S. [12][13]. Industry Trends - The medical aesthetics market is currently experiencing a transition, with hyaluronic acid and botulinum toxin being the leading products [10][11]. - The domestic market for botulinum toxin is still developing, with a low penetration rate compared to the U.S., indicating room for growth [13][14].